Company profile

Big Health

Mental Health & Digital Therapeutics

Company profile

About Big Health

Big Health is a digital therapeutics company specializing in mental health solutions that deliver evidence-based cognitive behavioral therapy through fully digital platforms. The company's flagship products include SleepioRx, an FDA-cleared prescription digital therapeutic for chronic insomnia disorder in adults 18+, and DaylightRx, an FDA-cleared treatment for generalized anxiety disorder (GAD) in adults 22+. Both treatments are designed to be used alongside usual care and are reimbursable through insurance. Big Health serves three primary markets: health systems and providers seeking reimbursable, FDA-cleared digital treatments to address patient demand and waitlists; health plans looking to scale access to first-line treatments while reducing costs; and employers aiming to provide employees with instant access to effective mental health care. The company also offers non-prescription workplace solutions including Sleepio for sleep improvement, Daylight for anxiety reduction, and Spark Direct for mood improvement. With over 500,000 patients treated and supported, Big Health's approach is grounded in extensive clinical validation, including 100+ peer-reviewed publications, 22 completed randomized controlled trials, and references in clinical guidelines such as those from the American College of Physicians. The company reports significant patient outcomes: 76% improvement in sleep for insomnia patients, 71% improvement in worry and anxiety, and 67% improvement in mood. Their solutions are HIPAA compliant and HITRUST certified, maintaining a 4+ App Store rating and a 9.8/10 client implementation satisfaction score.

Company description Big Health official website

Primary marketMental Health & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Big Health?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • chronic insomnia
  • depression symptoms
  • GAD
  • generalized anxiety disorder
  • insomnia disorder
  • low mood

Who it serves

  • Employers
  • Health Plans
  • Health Systems
  • Payers
  • Providers

Deployment & integration

Cloud Saas deployment with recorded integration context.

Geographic context

MarketsUnited Kingdom · United States
Company sourceOfficial website

Company milestones

Platform expansion

FDA clearance for SleepioRx and DaylightRx as prescription digital therapeutics. Achieved reimbursability through insurance with new billing codes. Treated 500,000+ patients.

Partnerships

Recorded partners

No partners are currently listed.

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

Daylight

Digital program to reduce worry and anxiety

Software · Cloud SaaSCompany source

DaylightRx

FDA-cleared digital CBT treatment for generalized anxiety disorder

Software · Cloud SaaSCompany source

Sleepio

Evidence-based digital program to improve sleep quality

Software · Cloud SaaSCompany source

SleepioRx

FDA-cleared digital CBT-I treatment for chronic insomnia disorder

Software · Cloud SaaSCompany source

Spark Direct

Digital program to improve mood and mental health

Software · Cloud SaaSCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

Evidence position

Publications, clinical validation, and regulatory records connected to this Company appear here.

Research

Publications & preprints

Proteome conserved multi-epitope-based vaccine construct against Nipah virus.

Naunyn-Schmiedeberg's archives of pharmacology · Aug 19, 2026

Oridonin loaded amphiphilic hyaluronic acid polymeric micelle with tunable redox sensitive property for CD44 targeted lung cancer therapy.

Discover nano · Jul 10, 2026

Comment on "Deep versus moderate neuromuscular blockade on postoperative recovery quality: a systematic review and meta-analysis of randomized controlled trials".

Journal of anesthesia · Jul 7, 2026

Preference for the modality of psychosocial treatment for anxiety in adults with comorbid anxiety and chronic musculoskeletal pain.

Cognitive behaviour therapy · Jul 1, 2026

Unlocking the Therapeutic Potential of Ganoderma lucidum: From Bioactive Compounds to Clinical Translation.

Phytotherapy research : PTR · Jul 1, 2026

Guideline clarification: dropout in FDA-cleared dCBT-I is comparable to pharmacotherapy and therapist-delivered CBT-I.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · Jul 1, 2026

Clinical validation

Clinical-trial records

Improving Sleep and Learning in Rehabilitation After Stroke, Part 2

NCT05511285 · Sponsor · RECRUITING

A Study of Digital Cognitive Behavioural Therapy for Insomnia in Fibromyalgia

NCT05962138 · Sponsor · COMPLETED

Perinatal Research on Improving Sleep and Mental Health

NCT05596318 · Mentioned · ACTIVE NOT RECRUITING

Improving Sleep in Rehabilitation After Stroke

NCT04272892 · Sponsor · COMPLETED

A Pilot Study of Digital Cognitive Behavioral Therapy for Veterans

NCT03688763 · Sponsor · TERMINATED

Frailty Intervention in Postoperative Hip Fracture Inpatients

NCT07027241 · Mentioned · NOT YET RECRUITING

Regulatory

Regulatory records

No linked records are currently available.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

76% improvement in sleep for insomnia patients

Clinical improvement with no serious side effects

71% improvement in worry and anxiety

Anxiety patients achieving clinical improvement with no serious side effects

67% improvement in mood

25% improvement in scores on validated screening measure

40% decrease in inpatient costs

Cost savings for health plans

20% decrease in outpatient costs

Cost savings for health plans

37% decrease in Rx claims costs

Cost savings for health plans

Josh

Managing anxiety as a caregiver

Gained useful coping mechanisms for ongoing anxiety management

Julia

Managing anxiety as a recent graduate in a new city

Increased control over anxiety through learned techniques

Sophia

Managing insomnia and jet lag for frequent travelers

Improved sleep quality through interactive CBT-I treatment

Wendy

Treating insomnia for anxious individuals

Feeling like herself again after treatment

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

No active leadership profiles are currently listed.

06 · Company updates

Updates from Big Health

Recent articles published on Big Health's official website.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Mental Health & Digital Therapeutics

Companies providing AI-powered mental health support, therapy platforms, mental wellness tracking, psychiatric care, digital therapeutics for mental health conditions, or AI-driven mental health screening and monitoring. Includes XR-based therapy, AI mental health screening infrastructure, and platforms supporting behavioral health for individuals and health systems.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon